Drugs / NeuroVax
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02200718 | Dec 2020 → Nov 2024 | multiple sclerosis | Immune Response BioPharma, Inc. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02149706 | Mar 2020 → Mar 2022 | multiple sclerosis | Immune Response BioPharma, Inc. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02057159 | Mar 2020 → Mar 2023 | secondary progressive multiple sclerosis | Immune Response BioPharma, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NeuroVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02057159 ↗ |
| Modality | Vaccine | “A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis” NCT02057159 ↗ |